It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

AstraZeneca (AZN) and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing authorization application (MAA) for their antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd).The MAA sought approval of Dato-DXd for treating adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase III study.The companies decided to withdraw the MAA for Dato-DXd in nonsquamous NSCLC following feedback ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AstraZeneca PLC ("AstraZeneca PLC" or the "Company") (NASDAQ: AZN) investors of a class action representing investors that bought securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"). AstraZeneca PLC investors have until February 21, 2025 to file a lead plaintiff motion. Investors are encouraged to contact ...

Core Insights - AstraZeneca's cancer drug Tagrisso has received EU approval for expanded use in non-small cell lung cancer (NSCLC) [10] - The approval is based on the phase III LAURA study, which demonstrated an 84% reduction in the risk of disease progression or death compared to placebo [6] - Tagrisso's sales reached $4.9 billion in the first nine months of 2024, reflecting a 15% year-over-year increase [16] Group 1: Approval and Indications - The eligible patient population for Tagrisso includes adults with locally advanced, unresectable NSCLC with specific EGFR mutations [1] - Tagrisso is now approved in the EU for five major indications based on the LAURA study, with ongoing reviews in other countries [2][10] - The drug is considered the standard of care for EGFR-mutated NSCLC in the first-line setting [11] Group 2: Clinical Data and Efficacy - The LAURA study showed a median progression-free survival of 39.1 months for Tagrisso-treated patients compared to 5.6 months for the placebo group [6] - The safety and tolerability profiles of Tagrisso were consistent with prior studies, with no new safety concerns identified [6] Group 3: Market Performance and Future Prospects - Tagrisso's sales growth is driven by strong demand as a first-line and adjuvant treatment [16] - AstraZeneca is evaluating Tagrisso in multiple-label expansion studies, which may further boost sales in the future [12] - AstraZeneca's shares have declined by 15% over the past three months, compared to a 17.4% decline in the industry [15]

U.K.-based pharmaceutical giant AstraZeneca (AZN 1.41%) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- as well as several other top executives -- were arrested following fraud-related investigations by the authorities. AstraZeneca expects a sales hit in China, one of its most important international markets.The drugmaker's issues in China have weighed heavily on its performance of late, and its stock is down by ab ...

NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public.So What: If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter category. Here's why they think AstraZeneca (AZN -0.54%), Eli Lilly (LLY 0.86%), and Vertex Pharmaceuticals (VRTX -0.08%) are unstoppable healthcare stocks to buy right now.An unstoppable stock at a great valuationDavid Jagielski (AstraZeneca): If you're buying a top growth stock, you often have to pay a heft ...

SAN FRANCISCO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in China as authorities there investigate the company for alleged fraud, illegal drug importation, and personal information breaches. The probe has caused AstraZeneca American Depositary Shares to decline sharply and raised serious concerns about the company’s business practices in one of its largest markets. Hagens Berman has opened an investigation and urges investors in AstraZeneca American Depos ...

AstraZeneca (AZN) has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with prostate cancer.The CAPItello-281 study evaluated the combination of Truqap, J&J’s (JNJ) Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).Results from the study showed that patients treated with this combin ...

There are plenty of growth stocks trading at obscenely high valuations right now. Part of the reason for that is the current enthusiasm for all things artificial intelligence (AI)-related. Some of those high valuations are because AI has sent some stock prices skyrocketing. However, there are other growth stocks out there being overlooked in the meantime.If you're on the hunt for some deals and are willing to be patient, three overlooked stocks you should consider loading up on right now are AstraZeneca (AZ ...